Common use of Authorization of Notes Clause in Contracts

Authorization of Notes. The Company will authorize the issue and sale of (i) $400,000,000 aggregate principal amount of its 3.86% Senior Notes, Series A, due December 3, 2025 (the “Series A Notes”) and (ii) $100,000,000 aggregate principal amount of its 3.86% Senior Notes, Series B, due January 14, 2026 (the “Series B Notes” and together with the Series A Notes, as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the forms set out in Schedule 1(a) and Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $400,000,000 85,000,000 aggregate principal amount of its 3.864.69% Senior Notes, Series A, due December 3April 1, 2025 2010 (the “Series A Notes”) and (iib) $100,000,000 65,000,000 aggregate principal amount of its 3.865.42% Senior Notes, Series B, due January 14April 1, 2026 2013 (the “Series B Notes” ”). The Series A Notes and together with the Series A B Notes are collectively referred to herein as the “Notes, as each may be amended, restated or otherwise modified from time ,” such term to time pursuant to Section 17 and including include any such notes issued in substitution therefor pursuant to Section 13, the “Notes”)13 of this Agreement. The Series A Notes and the Series B Notes shall be substantially in the forms form set out in Schedule Exhibit 1(a) and Schedule Exhibit 1(b), respectively, with such changes therefrom, if any, as may be approved by the Purchasers and the Company. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References B; references to a “Schedule” are references or an “Exhibit” are, unless otherwise specified, to a Schedule or an Exhibit attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specifiedAgreement.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $400,000,000 75,000,000 aggregate principal amount of its 3.863.70% Senior Guaranteed Notes, Series A, due December 3November 30, 2025 2030 (the “Series A Notes”) and (iib) $100,000,000 55,000,000 aggregate principal amount of its 3.863.82% Senior Guaranteed Notes, Series B, due January 14November 30, 2026 2031 (the “Series B Notes” ”, and together with the Series A Notes, the “Notes”, each as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the forms set out in Schedule 1(a) 1-A and Schedule 1(b)1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. B. References to “series” of Notes shall refer to the Series A Notes and the Series B Notes or all, as the context may require. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (i) $400,000,000 85,000,000 aggregate principal amount of its 3.862.17% Series A Senior Notes, Series Adue July 8, due December 3, 2025 2030 (the “Series A Notes”) and (ii) $100,000,000 75,000,000 aggregate principal amount of its 3.862.90% Series B Senior NotesNotes due July 8, Series B, due January 14, 2026 2040 (the “Series B Notes” ”; and together with the Series A Notes, the “Notes” (in each case as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes of the same Series issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes and Series B Notes shall be substantially in the forms form set out in Schedule 1(a) 1-A and Schedule 1(b)1-B, respectively. References to “Series” of Notes shall refer to the Series A Notes or Series B Notes, or all, as the context may require. Certain capitalized and other terms used in this Agreement are defined in Schedule A. B. References to a “Schedule” are or an “Exhibit” are, unless otherwise specified, references to a Schedule or an Exhibit attached to this Agreement unless otherwise specifiedAgreement. References to a “Section” are references to a Section of this Agreement unless otherwise specified. SECTION 2.

Authorization of Notes. The Company will authorize the issue and sale of (i) $400,000,000 90,000,000 aggregate principal amount of its 3.864.75% Senior Notes, Series AA due July 15, due December 3, 2025 2032 (the “Series A Notes”) and (ii) $100,000,000 85,000,000 aggregate principal amount of its 3.864.99% Senior Notes, Series BB due September 15, due January 14, 2026 2052 (the “Series B Notes,” and together with the Series A Notes, as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes and Series B Notes shall be substantially in the forms form set out in Schedule 1(a) and Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified. References to a “series” shall refer to each series of Notes or all series of Notes, as the context may require. SECTION 2.

Authorization of Notes. The Company Issuer will authorize the issue and sale of (i) $400,000,000 100,000,000 aggregate principal amount of its 3.864.08% Senior Notes, Series A, due December 3September 30, 2025 2026 (the “Series A Notes”) and (ii) $100,000,000 aggregate principal amount of its 3.864.24% Senior Notes, Series B, due January 14December 28, 2026 2028 (the “Series B Notes” ”). The Series A Notes and together with the Series A B Notes are collectively referred to herein as the “Notes,” such term to include any amendments, as each may be amended, restated restatements or otherwise modified other modifications from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes and the Series B Notes shall be substantially in the forms form set out in Schedule 1(a) and Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (i) $400,000,000 45,000,000 aggregate principal amount of its 3.864.29% Senior Notes, Series A, due December 3October 21, 2025 2020 (the “Series A Notes”) and (ii) $100,000,000 55,000,000 aggregate principal amount of its 3.864.94% Senior Notes, Series B, due January 148, 2026 2024 (the “Series B Notes” and together with the Series A Notes, Notes as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes and the Series B Notes shall be substantially in the forms set out in Schedule 1(a) Exhibits 1-A and Schedule 1(b)1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company Issuer will authorize the issue and sale of (i) $400,000,000 75,000,000 aggregate principal amount of its 3.864.10% Senior Guaranteed Notes, Series A, due December 3June 13, 2025 (the “Series A Notes”) and (ii) $100,000,000 aggregate principal amount of its 3.864.27% Senior Guaranteed Notes, Series B, due January 14June 13, 2026 2028 (the “Series B Notes” and together with the Series A Notes, as each may be amendedthe “Notes,” such term to include any amendments, restated restatements or otherwise modified modifications from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes and the Series B Notes shall be substantially in the forms form set out in Schedule 1(a) 1-A and Schedule 1(b)1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $400,000,000 60,000,000 aggregate principal amount of its 3.863.46% Senior Notes, Series A, due December 3January 19, 2025 2033 (the “Series A Notes”) and (iib) $100,000,000 240,000,000 aggregate principal amount of its 3.863.51% Senior Notes, Series B, due January 1419, 2026 2033 (the “Series B Notes” and ”, together with the Series A Notes, as each may be amendedthe “Notes”, restated such term to include any amendments, restatements or otherwise modified other modifications from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the forms form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b), respectively. Each series of notes is sometimes referred to herein as a “series”. Certain capitalized and other terms used in this Agreement are defined in Schedule A. B. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (i) $400,000,000 100,000,000 aggregate principal amount of its 3.861.59% Senior Notes, Series Adue June 15, due December 3, 2025 2026 (the “Series A Notes”) and (ii) $100,000,000 75,000,000 aggregate principal amount of its 3.861.64% Senior Notes, Series B, due January 14September 15, 2026 (the “Series B Notes,” and together with the Series A Notes, as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes and Series B Notes shall be substantially in the forms form set out in Schedule 1(a) and Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified. References to a “series” shall refer to each series of Notes or all series of Notes, as the context may require.

Authorization of Notes. The Company will authorize the issue and sale of (i) $400,000,000 75,000,000 aggregate principal amount of its 3.863.94% Series A Senior Notes, Series A, Notes due December 311, 2025 2023 (the “Series A Notes”) and (ii) $100,000,000 75,000,000 aggregate principal amount of its 3.864.04% Series B Senior NotesNotes due December 11, Series B, due January 14, 2026 2025 (the “Series B Notes” and and, together with the Series A Notes, the “Notes”), in each case as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes and Series B Notes shall be substantially in the forms form set out in Schedule 1(a) and Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. B. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (i) $400,000,000 28,750,000 aggregate principal amount of its 3.864.38% Senior Secured Notes, Series A, due December 3June 15, 2025 2028 (the “Series A Notes”) and (ii) $100,000,000 86,250,000 aggregate principal amount of its 3.864.58% Senior Secured Notes, Series B, due January 14June 15, 2026 2036 (the “Series B Notes” and and, together with the Series A Notes, as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes shall be substantially in the forms form set out in Schedule 1(a) and the Series B Notes shall be substantially in the form set out in Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $400,000,000 50,000,000 aggregate principal amount of its 3.864.23% Senior Guaranteed Notes, Series AA due September 1, due December 3, 2025 2022 (the “Series A Notes”) and (iib) $100,000,000 50,000,000 aggregate principal amount of its 3.864.65% Senior Guaranteed Notes, Series BB due October 13, due January 14, 2026 2027 (the “Series B Notes” and together with the Series A Notes, such term to include any such notes as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes and the Series B Notes shall be substantially in the forms form set out in Schedule 1(a) 1-A and Schedule 1(b)1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (ia) $400,000,000 325,000,000 aggregate principal amount of its 3.863.92% Guaranteed Senior Notes, Series A, due December 3May 21, 2025 (the “Series A Notes”) and (iib) $100,000,000 275,000,000 aggregate principal amount of its 3.864.02% Guaranteed Senior Notes, Series B, due January 14May 21, 2026 2027 (the “Series B Notes” and together with the Series A Notes, each as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Notes shall be substantially in the forms form set out in Schedule 1(a) 1-A and Schedule 1(b)1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (i) $400,000,000 63,000,000 aggregate principal amount of its 3.864.02% Senior Notes, Series A, due December 3January 22, 2025 2021 (the “Series A Notes”) and (ii) $100,000,000 87,000,000 aggregate principal amount of its 3.864.45% Senior Notes, Series B, due January 1422, 2026 2023 (the “Series B Notes” and together with the Series A Notes, Notes as each may be amended, restated or otherwise modified from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes and the Series B Notes shall be substantially in the forms set out in Schedule 1(a) Exhibits 1-A and Schedule 1(b)1-B, respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.

Authorization of Notes. The Company will authorize the issue and sale of (i) $400,000,000 150,000,000 aggregate principal amount of its 3.862.72% Senior Notes, Series A, due December 3February 27, 2025 2020 (the “Series A Notes”) ), and (ii) $100,000,000 350,000,000 aggregate principal amount of its 3.863.29% Senior Notes, Series B, due January 14February 27, 2026 2023 (the “Series B Notes” ”). The Series A Notes and together with the Series A B Notes are collectively referred to herein as the “Notes,” such term to include any amendments, as each may be amended, restated restatements or otherwise modified other modifications from time to time pursuant to Section 17 and including any such notes issued in substitution therefor pursuant to Section 13, the “Notes”). The Series A Notes and the Series B Notes shall be substantially in the forms form set out in Schedule 1(a) and Schedule 1(b), respectively. Certain capitalized and other terms used in this Agreement are defined in Schedule A. B. References to a “Schedule” are references to a Schedule attached to this Agreement unless otherwise specified. References to a “Section” are references to a Section of this Agreement unless otherwise specified.